Roche breast cancer drug improves survival of up to 62% in late-stage trial

Roche (OTCQX: RHHBY) subsidiary Genentech announced on Saturday promising results for its experimental breast cancer therapy, giredestrant.

In a Phase 3 trial, giredestrant, when used as part of a combination regimen, reduced the risk of disease progression or death by up to 62% in patients.

These findings highlight the potential of giredestrant as an effective treatment option in the fight against breast cancer. Further details and updates are expected as the research progresses.
https://seekingalpha.com/news/4505428-roche-posts-trial-data-breast-cancer-drug-giredestrant?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news

Leave a Reply

Your email address will not be published. Required fields are marked *